Internal R&D vs. CROs: AstraZeneca, Novartis Tout Advantages Of Staying In-House
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis reports savings of $100 mil. by decreasing its use of contract research organizations. AstraZeneca sees improved R&D productivity by relying less on CROs and by conducting clinical trials outside the U.S.
You may also be interested in...
GSK Predicts Outsourcing R&D To “Low-Cost” Countries Could Save $200 Mil.
Each outsourced clinical trial patient could save GSK up to $15,000, CEO Garnier estimates. The company is exploring a number of ways to control R&D costs, the exec says, citing electronic data capture as another potential option.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.